RNTECH and DNAVision announce a co-marketing agreement to offer complete solution for biomarker and target discovery


Privately held companies DNAVision and RNTECH announced that they have signed a co-marketing agreement under which the companies will jointly offer an integrated package of high quality material biological bank, gene expression and genotyping technologies. Post-genome era discovery processes must be based upon the combination of two key components: high quality, severely selected biological material associated with diagnostic and clinical data from large scale patient cohorts and state of the art technology platforms including genomics, proteomics and bioinformatics platforms.

The RNTECH/DNAVision offer associates these key components, creating a opportunity for pharmaceutical and biotechnology industries to access discovery and development expertise in oncology for biomarker and drugable target discovery and development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances